Introduction
To ensure proper recombination events during meiosis, homologous chromosomes need to be aligned next to each other to undergo recombination events (Kleckner, 2006; Qiao et al., 2012) . Pairing of homologous chromosomes is mediated by a complicated, well organized protein complex structure known as the syneptonemal complex, which is a large structure composed of many meiosis-specific proteins such as synemtonemal complex proteins 1, 2 and 3 (SYCP1, SYCP2 and SYCP3; Page & Hawley, 2004; Fraune et al., 2012) .
Syneptonemal complex formation is initiated in the early stage of meiotic prophase I (Zickler, 2006) . The syneptonemal complex is composed of three distinct structures: axial elements (AEs), lateral elements (LEs) and central elements (CEs) . For proper pairing of the homologous chromosomes during meiotic prophase I, axial elements (AEs), which are composed of SYCP2 and SYCP3, are formed along each chromosome. Subsequently, the two AEs associate with linker parts called lateral elements (LEs), which contain SYCP1 as the main protein component. Finally, the central element (CE), which is composed of SYCE1 and SYCE2, connects to the AE via the LE to form the full syneptonemal structure (Zickler, 2006; Fraune et al., 2012; Bisig et al., 2012) . Failure of proper assembly of the syneptonemal complex leads to infertility or aneuploidy in mammals (Hassold & Hunt, 2001; Roos et al., 2013) . Despite the importance of this complex, structural information is still limited. SYCP1 is the main structural constituent of LEs and is known to form multistranded, cross-striated fibres in vivo (Yuan et al., 1998) . SYCP1 is a well known meiosis marker that is also known to be prognostic in early-stage cancers, including breast, glioma and ovarian cancers (Tü reci et al., 1998). Human SYCP1 is a 993-amino-acid protein with several coiled-coil domains. In the present study, we overexpressed, purified and crystallized the middle part of the SYCP1 coiled-coil domain (SYCP1 662-750 ) as a first step towards the elucidation of the molecular structure of the syneptonemal complex. Although SYCP1 usually forms fibres in vitro, we were able to obtain the overexpressed construct by designing, constructing and testing many plasmid constructs. SYCP1 662-750 was the most well behaved and well expressed construct among these. Overexpressed human SYCP1 662-750 was purified by affinity chromatography followed by gel-filtration chromatography and diffracting SYCP1 662-750 crystals were obtained. X-ray diffraction data were collected to a resolution of 3.0 Å from a crystal belonging to space group I4, with unit-cell parameters a = 41.95, b = 41.95, c = 318.78 Å . The asymmetric unit was estimated to contain two molecules.
Materials and methods

Macromolecule production
To express C-terminally histidine-tagged SYCP1 662-750 , the coiled-coil domain including the middle region of SCP1, which corresponds to residues Asp662-Glu750, was cloned into pET-24a. The plasmid was then transformed into Escherichia coli BL21 competent cells, after which its expression in LB medium was induced by treatment with 0.5 mM isopropyl -d-1-thiogalactopyranoside (IPTG) overnight at 293 K when the OD 600 reached 0.8. Cells expressing SYCP1 662-750 were pelleted by centrifugation, resuspended and lysed by sonication in 25 ml lysis buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 25 mM imidazole). The lysate was then centrifuged at 16 000g for 30 min at 277 K, after which the supernatant fractions were applied onto a gravity-flow column (Bio-Rad) packed with Ni-NTA affinity resin (Qiagen). The unbound bacterial proteins were then removed from the column using 150 ml washing buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 60 mM imidazole). The C-terminally histidine-tagged SYCP1 662-750 was then eluted from the column using elution buffer (20 mM Tris-HCl buffer pH 7.9, 500 mM NaCl, 250 mM imidazole). The elution fractions were subsequently collected in 0.5 ml volumes to give a total volume of 5.0 ml. The collected SYCP1 662-750 was pooled, concentrated and applied onto a Superdex 200 gel-filtration column (GE Healthcare) that had been pre-equilibrated with a solution consisting of 20 mM sodium citrate pH 5.0, 150 mM NaCl. SYCP1 662-750 (molecular mass 11 800 Da) eluted at around 14-15 ml and was collected and concentrated to 8-9 mg ml À1 . The protein concentration was measured using a protein-assay kit (Bio-Rad) and was determined by the Bradford method (Bradford, 1976) . Purified SYCP1 662-750 contained the additional residues LEHHHHHH at the C-terminus. The additional residues, including the hexahistidine tag, at the C-terminus were not removed. The purified protein was used directly in crystallization trials. The purification procedures are summarized in Table 1 .
Crystallization
The crystallization conditions were initially screened at 293 K by the hanging-drop vapour-diffusion method using screening kits from Hampton Research (Crystal Screen, Crystal Screen 2, Crystal Screen Cryo, SaltRx and Natrix) and Rigaku Reagents (Wizard I, II, III and IV). The initial crystals were grown on plates by equilibrating a mixture consisting of 1 ml protein solution (8.5 mg ml À1 protein in 20 mM sodium citrate pH 5.0, 150 mM NaCl) and 1 ml solution No. 48 from Crystal Screen Cryo [Hampton Research; 1.6 M ammonium phosphate monobasic, 20%(v/v) glycerol, 0.08 M Tris-HCl pH 8.5] against 0.4 ml reservoir solution. After optimization, crystals appeared within 4 d and grew to maximum dimensions of 0.05 Â 0.05 Â 0.4 mm, with the best quality occurring in the presence of 1.9 M ammonium phosphate, 16%(v/v) glycerol, 0.08 M Tris-HCl pH 8.0. The crystals diffracted to a resolution of 3.0 Å . A summary of the crystallization is provided in Table 2 .
Data collection and processing
For data collection, the crystals were transiently soaked in cryoprotectant solution and directly cooled in liquid nitrogen. During this process, providing an additional 30%(v/v) glycerol [1.5 ml 60%(v/v) glycerol was added to 1.5 ml mother liquor] in the crystal drop was sufficient as a cryoprotectant. A 3.0 Å resolution native diffraction data set was collected on beamline 5C (SB II) of the Pohang Accelerator Laboratory (PAL), Republic of Korea. The data set was indexed and processed using HKL-2000 (Otwinowski & Minor, 1997) . Diffraction data statistics are given in Table 3 . Table 1 Macromolecule-production information.
Results and discussion
Source organism
Human DNA source GenBank NM_003176 Forward primer recombination and proper chromosome segregation.
Although several electron-microscopic (EM) analyses have shown the overall structure of the syneptonemal complex (Gillies, 1975; Ollinger et al., 2005; Comings & Okada, 1971) , the atomic structure of this complicated molecule is completely unknown. To obtain a better understanding of this process, we overexpressed, purified and crystallized the middle part of SYCP1 (SYCP1 662-750 ). SYCP1 is the main component of the lateral element of the syneptonemal complex. We made 32 expression constructs, including fulllength SYCP1. Among them, SYCP1 662-750 , which contains amino acids 662-750, and SYCP1 662-801 , which contains amino acid 662-801, were well expressed and were used to produce the coiled-coil domain of SYCP1. Although our target, SYCP1 662-750 , is only the middle part of the coiled-coil domain of SYCP1, the target domain used in this study will be representative of the overall structure of SYCP1 because the majority of the structure of SYCP1 is known to be composed of coiled-coil domain. His-tag affinity chromatography followed by gel-filtration chromatography produced approximately 95% pure SYCP1 662-750 , and no contaminating bands were observed upon SDS-PAGE analysis (Fig. 1) . The calculated monomeric molecular weight of SYCP1 662-750 , including the additional residues at the C-terminus, was 11 800 Da, and its elution peak from size-exclusion chromatography suggests that it exists as a dimer in solution. A gel-filtration standard (Bio-Rad) containing a mixture of molecular-weight markers (thyroglobulin, 670 000 Da; globulin, 158 000 Da; ovalbumin, 44 000 Da; myoglobulin, 17 000 Da; vitamin B 12 , 1350 Da) was used for size calibration.
An Crystals of SYCP1 662-750 . Crystals grew in 4 d in the presence of 1.9 M ammonium phosphate, 16%(v/v) glycerol, 0.08 M Tris-HCl pH 8.0. The approximate dimensions of the crystals were 0.05 Â 0.05 Â 0.4 mm.
Figure 3
A diffraction image (1 oscillation) from an SYCP1 662-750 crystal. The resolution limit of 3.0 Å is shown as a circle. 
Figure 1
Purification of SYCP1 662-750 . Size-exclusion chromatography and SDS-PAGE of SYCP1 662-750 . The numbered fractions were loaded onto SDS-PAGE (inset).
pH values led to better crystals that were suitable for diffraction in the presence of 1.9 M ammonium phosphate, 16%(v/v) glycerol, 0.08 M Tris-HCl pH 8.0 (Fig. 2) . The optimized crystals grew to dimensions of 0.05 Â 0.05 Â 0.4 mm in 4 d and diffracted to 3.0 Å resolution (Fig. 3) . The crystals belonged to space group I4, with unit-cell parameters a = 41.95, b = 41.95, c = 318.78 Å .
Assuming the presence of two monomers or one dimer in the crystallographic asymmetric unit, the Matthews coefficient (V M ) was calculated to be 2.78 Å 3 Da À1 , which corresponds to a solvent content of 55.82% (Matthews, 1968) . The molecularreplacement phasing method was conducted using Phaser (McCoy, 2007) ; several coiled-coil domains, including fibrinogen (PDB entry 1ei3; Yang et al., 2000) , which has 22% sequence identity to SYCP1 662-750 , and HAMP (PDB entry 3zrv; Ferris et al., 2012) , which has 15% sequence identity to SYCP1 662-750 , were used as search models. Because of poor models, an MR solution has not yet been obtained. To overcome the phasing problem, we also produced seleniumsubstituted crystals using similar conditions and are currently conducting SAD phasing using SOLVE/RESOLVE (Terwilliger, 2004) .
